Sign in Subscribe

Alex Chompff

Pooled Analysis Identifies Predictive Biomarkers for Cetuximab Rechallenge in Metastatic Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Pooled Analysis Identifies Predictive Biomarkers for Cetuximab Rechallenge in Metastatic Colorectal Cancer Pooled analysis of 180 patients from the CAVE and CAVE-2 studies investigates clinical variables that predict response to cetuximab rechallenge (with or without avelumab) in patients with circulating tumor DNA RAS/

HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance

Skip to content The CRC Digest ▸ TREATMENT HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance Narrative review outlines practical patient selection and treatment sequencing for HER2-targeted therapies in metastatic colorectal cancer, focusing on RAS wild-type disease with HER2 overexpression or ERBB2 amplification, including dual HER2

Extended Follow-Up Shows Durable Responses with Dual Immunotherapy in MSS Metastatic Colorectal Cancer Without Liver Metastases

Skip to content The CRC Digest ◆ TRIAL DATA Extended Follow-Up Shows Durable Responses with Dual Immunotherapy in MSS Metastatic Colorectal Cancer Without Liver Metastases Phase 1b trial of botensilimab (Fc-enhanced anti-CTLA-4) plus balstilimab (anti-PD-1) in patients with microsatellite-stable metastatic colorectal cancer and no active liver metastases reports extended follow-up data

CRC Research Update — August 28, 2026

Today's colorectal cancer research highlights

Combination therapy targets KRAS G12C mutation in metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Combination therapy targets KRAS G12C mutation in metastatic CRC The Lancet Oncology published results showing encouraging antitumor activity of ifebemtinib combined with garsorasib in previously treated patients whose metastatic colorectal cancer harbors the KRAS G12C mutation. (The Manila Times) This content is informational

Age-stratified analysis reveals CEMIP elevation in early-onset CRC

Skip to content The CRC Digest ◇ RESEARCH Age-stratified analysis reveals CEMIP elevation in early-onset CRC Transcriptomic profiling identified CEMIP, NKD2, and FOXQ1 as elevated in colorectal cancer diagnosed before age 50, with CEMIP showing the strongest association with survival outcomes. (Genes) This content is informational only and does not constitute

Study explores caregiving experiences and support needs in Kazakhstan

Skip to content The CRC Digest ♥ LIVING WITH CRC Study explores caregiving experiences and support needs in Kazakhstan A qualitative study of 21 family caregivers in Kazakhstan examined caregiving experiences, burden, supportive care needs, and coping strategies among those caring for patients with colorectal cancer. (Nursing Reports) This content is

Australian audit finds gaps in surveillance colonoscopy guideline adherence

Skip to content The CRC Digest ▪ SCREENING Australian audit finds gaps in surveillance colonoscopy guideline adherence A clinical audit of six Victorian public hospitals assessed concordance of endoscopist-recommended surveillance colonoscopy intervals with 2018 Australian Cancer Council guidelines, identifying opportunities to improve adherence. (Australian Health Review) This content is informational only

CEMIP identified as candidate biomarker in early-onset colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH CEMIP identified as candidate biomarker in early-onset colorectal cancer Researchers identified CEMIP as elevated in colorectal cancer diagnosed before age 50 and associated with poorer overall survival, with evidence linking it to PTCH1-related Hedgehog signaling pathways. (Genes) This content is informational only and

Ifebemtinib plus garsorasib shows antitumor activity in KRAS G12C metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Ifebemtinib plus garsorasib shows antitumor activity in KRAS G12C metastatic colorectal cancer A combination of ifebemtinib and garsorasib demonstrated encouraging antitumor activity in previously treated metastatic colorectal cancer patients with KRAS G12C mutations, according to results published in The Lancet Oncology. (The Manila